Latest News - DexCom
Top Corporates Hub
DexCom
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
19.05.2026 14:55
DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.
14. OURA
19.05.2026 05:55
OURA, at the center of the tracking of the health and wellness boom, ranks No. 14 on CNBC’s 2026 Disruptor 50 list.
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
18.05.2026 11:31
SAN DIEGO & EDINBURGH, Scotland, May 18, 2026--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon.
Did New Long-Term Targets and US$1 Billion Buyback Just Shift DexCom's (DXCM) Investment Narrative?
17.05.2026 05:14
Earlier this week, DexCom held its 2026 Investor Day, outlining long-term targets for at least 10% annual organic revenue growth through 2030, plans for margin expansion, and a new US$1.00 billion share repurchase program running until June 30, 2027, following the completion of its prior US$500.00 million buyback. At the same time, DexCom announced governance changes, including working with activist investor Elliott Investment Management to add two independent directors and create an...
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
16.05.2026 13:08
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement. President and Chief Executive Officer Jake Leach said the company’s next phase
DexCom (DXCM) Posts Upbeat 2026, Climbs 6.6%
16.05.2026 01:43
DexCom Inc. (NASDAQ:DXCM) is one of the 10 Stocks Dominating With Powerful Gains. DexCom snapped a two-day loss on Friday, jumping 6.59 percent to close at $61.63 apiece, as investor sentiment was bolstered by its higher growth outlook for the full-year period. At its investor day on Thursday, DexCom Inc. (NASDAQ:DXCM) announced an organic revenue […]
DexCom, Inc. announces an Equity Buyback for $1,000 million worth of its shares.
15.05.2026 09:05
DexCom, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its shares. The plan will be valid till June 30, 2027....
Tranche Update on DexCom, Inc.'s Equity Buyback Plan announced on May 1, 2025.
15.05.2026 09:05
From January 1, 2026 to May 14, 2026, the company has repurchased 75 shares, representing 0.000019% for $0.005036 million. With this, the company has completed the repurchase of 7,669,071 shares,...
Is DexCom (DXCM) Share Weakness Creating A Valuation Opportunity For Investors?
13.05.2026 10:28
If you are wondering whether DexCom's current share price still reflects its potential, the recent valuation signals give you plenty to think about. The stock closed at US$61.14, with a gain of 2.8% over the last week, while returns over the last month, year to date, and past year show declines of 4.5%, 8.1%, and 27.3% respectively. Over three and five years the stock is down 48.5% and 25.9%. These moves have kept DexCom firmly on investors' watchlists, with ongoing attention on how...
ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System
12.05.2026 07:30
New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands planned for later this summerEnables insulin automation to be controlled directly from the user’s smartphone, rather than a separate dedicated handsetStarting on Kaleido today with Diabeloop’s DBLG1 algorithm is the fastest path to Kaleido with DBLG2 and Dexcom G7 UTRECHT, The Netherlands, May 12, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device
DexCom's (NASDAQ:DXCM) Strong Earnings Are Of Good Quality
07.05.2026 11:46
When companies post strong earnings, the stock generally performs well, just like DexCom, Inc.'s ( NASDAQ:DXCM ) stock...
DexCom (DXCM) Reports Q1 2026 Revenue of $1.19B with 15% Growth
07.05.2026 04:56
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to invest in for the next 2 years. On April 30, DexCom reported Q1 2026 revenue of $1.192 billion, representing a 15% year-over-year increase on a reported basis. Growth was driven by an 11% rise in US revenue and a 26% jump in international sales. […]
Alert from law firm tagged to Dexcom withdrawn
05.05.2026 15:55
An alert tagged to Dexcom from a law firm's press release was inadvertently published and has been withdrawn.There will be no substitute.Story number: nTUABP30SZStory date: 05/05/2026Story...
Dexcom to Host Investor Day on May 14, 2026
05.05.2026 12:30
SAN DIEGO, May 05, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook.
Should DexCom’s Margin Gains and Expanded Coverage Require Action From DexCom (DXCM) Investors?
03.05.2026 02:15
DexCom, Inc. reported past first-quarter 2026 results with revenue of US$1,191.9 million, net income of US$199.5 million, and diluted EPS of US$0.51, while reaffirming full-year revenue guidance of US$5.16 billion to US$5.25 billion. The company coupled this financial strength with broader access for its continuous glucose monitoring systems, including new coverage for millions of type 2 non-insulin users and higher profitability guidance. Next, we’ll examine how DexCom’s stronger margins...
DXCM Q1 Deep Dive: U.S. Growth Moderates as Product Momentum and Coverage Expansion Drive Strategy
02.05.2026 09:24
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 15% year on year to $1.19 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 19% above analysts’ consensus estimates.
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook
01.05.2026 11:25
Dexcom has opted not to raise its FY26 revenue outlook due to the current geopolitical environment.
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals
01.05.2026 11:10
DexCom (DXCM) exemplifies GARP investing with strong growth, reasonable valuation, and solid financial health. This affordable growth stock combines 27% EPS growth with a PEG ratio indicating fair pricing.
BTIG Remains Bullish on DexCom, Inc. (DXCM)
01.05.2026 07:59
DexCom, Inc. (NASDAQ:DXCM) is one of the best medical device stocks to invest in right now. BTIG cut the price target on DexCom, Inc. (NASDAQ:DXCM) to $80 from $85 on April 13 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note on Medical Technology, with […]
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ...
01.05.2026 07:18
DexCom Inc (DXCM) reports a robust 15% revenue increase, driven by international demand and strategic product launches, despite challenges in the US market.